Introduction {#Sec1}
============

Secukinumab, a human monoclonal antibody that selectively binds to and neutralizes interleukin-17A, is approved for the treatment of moderate-to-severe plaque psoriasis in the United States and Europe. In phase 3 studies, the efficacy of secukinumab has been demonstrated based on significant improvements in Psoriasis Area and Severity Index (PASI) responses compared with placebo, etanercept, and ustekinumab \[[@CR1]--[@CR4]\].

Although PASI is infrequently used in clinical practice, an improvement from Baseline of at least 75% (PASI 75) is well established in clinical trials as a clinically meaningful reduction in disease severity that also correlates with improvements in patients' quality of life \[[@CR5]\]. As PASI includes separate assessments for psoriasis signs (erythema, thickening, and scaling) on the head and neck, trunk (including the genitals), upper limbs, and lower limbs \[[@CR5]\], PASI results can be adequately used to assess the effects of treatment on specific body regions. It is important to evaluate improvements in psoriasis on different body regions as psoriasis, on certain areas, disproportionately impacts quality of life \[[@CR6], [@CR7]\]. Accordingly, patients' perceived improvement and satisfaction with treatment may be differently impacted based on the areas where improvement occurs.

In this issue of Dermatology and Therapy, Kircik et al. reported the robust and sustained clearance of psoriatic lesions on the head and neck following treatment with secukinumab 300 mg and secukinumab 150 mg in a pooled population from four phase 3 trials \[[@CR8]\]. Here we present the efficacy of secukinumab (300 or 150 mg), on the trunk, upper limbs, and lower limbs from the same pooled population, using PASI 90 and PASI 100 response rates. These levels of improvement have become the new benchmarks for success in treating patients with moderate-to-severe psoriasis, especially with new biologic agents \[[@CR9]\].

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

Pooled data to Week 52 from four phase 3, randomized, placebo-controlled, double-blind studies \[Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis (ERASURE, ClinicalTrials.gov identifier: NCT01365455), Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis (FIXTURE, ClinicalTrials.gov identifier: NCT01358578), First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis (FEATURE, ClinicalTrials.gov identifier: NCT01555125), and Judging the Efficacy of Secukinumab in Patients With Psoriasis Using Autoinjector: A Clinical Trial Evaluation Treatment Results (JUNCTURE, ClinicalTrials.gov identifier: NCT01636687)\] of secukinumab in patients with moderate-to-severe plaque psoriasis were used for this analysis. A detailed description of the design for these trials can be found elsewhere \[[@CR1]--[@CR3]\]. Briefly, subjects received secukinumab (300 or 150 mg) at Baseline, Weeks 1, 2 and 3, and then every 4 weeks from Week 4 to 48. At Week 12, patients receiving placebo were randomized to secukinumab.

Study Population {#Sec4}
----------------

All studies included adults 18 years of age or older with a diagnosis of moderate-to-severe plaque psoriasis of at least 6 months prior to randomization that was poorly controlled with topical, phototherapy, and/or systemic therapy. To meet the definition of moderate-to-severe psoriasis, patients were required to have a composite PASI score ≥12, an Investigator's Global Assessment modified 2011 (IGA mod 2011) \[[@CR10]\] score ≥3, and total affected body surface area ≥10% at Baseline. To be included in the subanalysis for a given body region, patients were required to have a PASI score ≥12 for that specific body region and psoriasis covering ≥10% of the surface area of that region. Exclusion criteria included active, ongoing inflammatory diseases; active, ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection; or an underlying condition significantly immunocompromising the patient and/or placing the patient at unacceptable risk for receiving an immunomodulatory therapy (e.g., lymphoproliferative disease, malignancy, history of malignancy within the past 5 years; and/or past medical history of human immunodeficiency virus, hepatitis B, or hepatitis C).

Efficacy Assessments {#Sec5}
--------------------

In all 4 trials, the coprimary efficacy variables were PASI 75 response rates and IGA mod 2011 0/1 response rates at Week 12. The proportion of patients achieving PASI 90 at Week 12 was a key secondary endpoint in all trials.

Statistical Analysis {#Sec6}
--------------------

Efficacy data from the ERASURE, FIXTURE, FEATURE, and JUNCTURE trials were pooled through Week 52. Missing values were imputed by multiple imputation (MI). The SAS (version 9.3, SAS Institute, Cary, NC, USA) MI procedure was used to generate data sets for 500 imputations. The MI method was used in this study because it more accurately reflects real world response rates than the non-responder imputation method, which underestimates PASI responses \[[@CR11]\]. This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.

Results {#Sec7}
=======

Patient Demographics {#Sec8}
--------------------

Of the 2403 randomized patients, the number eligible for the evaluation of each body region (PASI score ≥12 for that specific body region and psoriasis covering ≥10% of the surface area of that region) who received secukinumab were 1092 for the trunk, 1233 for the upper limbs, and 1309 for the lower limbs. As reported by Kircik et al. \[[@CR8]\], demographic characteristics for the pooled population were well balanced across secukinumab treatment groups \[[@CR8]\]. Briefly, approximately 70% of patients were male and White and mean PASI scores at randomization were approximately 23.

Efficacy {#Sec9}
--------

At Week 12 and Week 52, PASI 75 subscore responses on the trunk, upper limbs, and lower limbs were high for patients receiving both secukinumab 300 mg and secukinumab 150 mg. PASI 75 subscore response rates at Week 12 were well maintained up to Week 52. The most robust efficacy was observed on the trunk, followed by the upper limbs and then the lower limbs (Table [1](#Tab1){ref-type="table"}).Table 1Percentage of patients who achieved PASI 75 at Week 12 and Week 52 by body regionParameterSecukinumab 300 mgSecukinumab 150 mgWeek 12 TPASI 7588.8% (488/550)78.0% (423/542) ULPASI 7583.5% (510/611)72.9% (454/622) LLPASI 7581.2% (530/652)66.1% (434/657)Week 52 TPASI 7590.9% (500/550)82.1% (445/542) ULPASI 7585.9% (525/611)71.6% (445/622) LLPASI 7582.1% (535/652)66.3% (436/657)Missing values were imputed by multiple imputation*LLPASI* lower limb Psoriasis Area and Severity Index, *TPASI* trunk Psoriasis Area and Severity Index, *ULPASI* upper limb Psoriasis Area and Severity Index

PASI 90 and PASI 100 subscore response rates to Week 52 for each body region are shown in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, respectively. For all body regions, initial PASI 90 and PASI 100 subscore responses were maintained to Week 52. At Week 16, a numerically greater proportion of patients achieved skin clearance on the trunk than on the upper limbs or the lower limbs. Trunk (T) PASI 90 and TPASI 100 responses were achieved by 82.5% and 70.0% of patients receiving secukinumab 300 mg, respectively, and by 70.8% and 58.9% of patients receiving secukinumab 150 mg, respectively. Upper limb (UL) PASI 90 and ULPASI 100 responses were achieved by 72.1% and 61.4% of patients receiving secukinumab 300 mg, respectively, and by 57.6% and 43.7% of patients receiving secukinumab 150 mg, respectively. Lower limb (LL) PASI 90 and LLPASI 100 responses were achieved by 68.9% and 52.9% of patients receiving secukinumab 300 mg, respectively, and by 50.5% and 35.8% of patients receiving secukinumab 150 mg, respectively.Fig. 1PASI 90 subscore response rates by body region. Missing values were imputed by multiple imputation. Clinical response rates for **a** trunk, **b** upper limbs, and **c** lower limbs from Baseline to Week 52. *n* Represents the number of evaluable subjects. *PASI 90* 90% improvement from Baseline Psoriasis Area and Severity Index Fig. 2PASI 100 subscore response rates by body region. Missing values were imputed by multiple imputation. Clinical response rates for **a** trunk, **b** upper limbs, and **c** lower limbs from Baseline to Week 52. *n* Represents the number of evaluable subjects. *PASI 100* 100% improvement from Baseline Psoriasis Area and Severity Index

The trend for a greater response to secukinumab on the trunk than on the upper limbs or the lower limbs was maintained up to Week 52. At Week 52, TPASI 90 and TPASI 100 responses were achieved by 78.4% and 71.1% of patients receiving secukinumab 300 mg, respectively, and by 66.3% and 56.9% of patients receiving secukinumab 150 mg, respectively. ULPASI 90 and ULPASI 100 responses were achieved by 67.3% and 59.1% of patients receiving secukinumab 300 mg, respectively, and by 50.3% and 43.3% of patients receiving secukinumab 150 mg, respectively. LLPASI 90 and LLPASI 100 responses were achieved by 63.9% and 55.3% of patients receiving secukinumab 300 mg, respectively, and by 45.1% and 36.4% of patients receiving secukinumab 150 mg, respectively.

As shown in Fig. [3](#Fig3){ref-type="fig"}, treatment with secukinumab rapidly improved plaque psoriasis, with a 50% reduction in mean PASI subscore with secukinumab 300 mg observed after 2.8 weeks \[95% confidence interval (CI) 2.6--2.9\] on the trunk, 2.9 weeks (95% CI 2.8--3.1) on the upper limbs, and 3.4 weeks (95% CI 3.2--3.6) on the lower limbs. With administration of secukinumab 150 mg, a 50% reduction in mean PASI subscore was observed after 3.4 weeks (95% CI 3.2--3.6) on the trunk, 3.7 weeks (95% CI 3.5--3.9) on the upper limbs, and 4.5 weeks (95% CI 4.1--4.9) on the lower limbs.Fig. 3Percent change in mean PASI subscore over time by body region. A repeated-measures, mixed-effects model was used to analyze the mean percent change from Baseline for **a** TPASI, **b** ULPASI, and **c** LLPASI subscores. The median time to a 50% reduction in mean PASI subscore was estimated from parametric bootstrap samples with the use of linear interpolation between time points. *CI* confidence interval, *LLPASI* lower limb Psoriasis Area and Severity Index, *TPASI* trunk Psoriasis Area and Severity Index, *ULPASI* upper limb Psoriasis Area and Severity Index

Discussion {#Sec10}
==========

Results of this pooled analysis show that secukinumab provides rapid and sustained efficacy over 52 weeks in treating patients with moderate-to-severe plaque psoriasis on the trunk, upper limbs, and lower limbs. These findings are consistent with the efficacy of secukinumab observed for psoriasis lesions affecting the head and neck \[[@CR8]\], indicating that secukinumab is effective for treating psoriasis regardless of the body region affected. The most robust PASI 90/100 subscore responses at Week 52 with secukinumab 300 mg occurred on the trunk (78.4%/71.1%) and the head and neck (76.0%/68.7%) \[[@CR8]\] region. Additionally, a large proportion of patients also achieved PASI 90/100 subscore responses with secukinumab 300 mg on the upper limbs (67.3%/59.1%) and the lower limbs (63.9%/55.3%) at Week 52. A similar trend was observed with secukinumab 150 mg at Week 52 between the trunk (66.3%/56.9%), head and neck (61.4%/53.1%) \[[@CR8]\], upper limbs (50.3%/43.3%), and lower limbs (45.1%/36.4%).

More rapid responses were observed with the treatment of secukinumab 300 mg compared with secukinumab 150 mg across all body regions. The time to a 50% mean reduction in PASI subscore was quickest with secukinumab 300 mg for the head and neck region (2.0 weeks) \[[@CR8]\], followed by the trunk (2.8 weeks), upper limbs (2.9 weeks), and lower limbs (3.4 weeks). A similar trend was reported for secukinumab 150 mg, with the time to a 50% mean reduction in PASI subscore occurring first in the head and neck region (2.7 weeks) \[[@CR8]\] followed by the trunk (3.4 weeks), upper limbs (3.7 weeks), and lower limbs (4.5 weeks). Additionally, in ERASURE and FIXTURE, improvement in PASI scores were mirrored by significant improvements in patient-reported symptoms of itching, pain, and scaling compared with placebo up to Week 12 as recorded by the Psoriasis Symptom Diary© \[[@CR12]\]. A limitation of this study is the lack of a control group after Week 12.

Safety findings for the pooled population used in this analysis are reported separately by Kircik et al. \[[@CR8]\]. Briefly, adverse events were observed at a similar rate between both secukinumab doses, and the most common adverse events through Week 52 were nasopharyngitis and headache.

Findings from this study are consistent with results from other studies that evaluated treatment efficacy by body region. In these studies, as well as in clinical practice, it has been observed that biologic treatment response typically starts on the head and upper body and progresses downward to lower body regions and extremities \[[@CR13], [@CR14]\]. For example, after 16 weeks of treatment with the tumor necrosis factor-alpha inhibitor adalimumab, the greatest PASI 100 subscore response rates were reported on the head and neck (55.7%) and the trunk (49.1%) compared with the upper limbs (33.3%) and the lower limbs (30.6%) \[[@CR14]\].

Conclusion {#Sec11}
==========

In conclusion, the results of our pooled analysis demonstrated that, on the trunk, upper limbs, and lower limbs, secukinumab---especially 300 mg---provided PASI 75, PASI 90, and PASI 100 subscore improvements that were rapid and sustained. Disease clearance occurred rapidly on highly visible areas of the skin, which is likely to produce a significant emotional improvement for patients. This study, and the accompanying article by Kircik et al. \[[@CR8]\], demonstrate the strong efficacy of secukinumab on different body regions. Overall, these results indicate that clear or almost clear skin (PASI 100 or PASI 90) are appropriate treatment goals for patients with moderate-to-severe plaque psoriasis who are treated with secukinumab.
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